



ELSEVIER



CrossMark

Experimental Hematology 2016;44:895–901

**Experimental  
Hematology****REVIEW****Aging of hematopoietic stem cells: DNA damage and mutations?**Bettina M. Moehrle<sup>a</sup> and Hartmut Geiger<sup>a,b,c</sup><sup>a</sup>Institute for Molecular Medicine, Ulm University, Ulm, Germany; <sup>b</sup>Aging Research Center, Ulm University, Ulm, Germany; <sup>c</sup>Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

(Received 21 June 2016; accepted 27 June 2016)

**Aging in the hematopoietic system and the stem cell niche contributes to aging-associated phenotypes of hematopoietic stem cells (HSCs), including leukemia and aging-associated immune remodeling. Among others, the DNA damage theory of aging of HSCs is well established, based on the detection of a significantly larger amount of  $\gamma$ H2AX foci and a higher tail moment in the comet assay, both initially thought to be associated with DNA damage in aged HSCs compared with young cells, and bone marrow failure in animals devoid of DNA repair factors. Novel data on the increase in and nature of DNA mutations in the hematopoietic system with age, the quality of the DNA damage response in aged HSCs, and the nature of  $\gamma$ H2AX foci question a direct link between DNA damage and the DNA damage response and aging of HSCs, and rather favor changes in epigenetics, splicing-factors or three-dimensional architecture of the cell as major cell intrinsic factors of HSCs aging. Aging of HSCs is also driven by a strong contribution of aging of the niche. This review discusses the DNA damage theory of HSC aging in the light of these novel mechanisms of aging of HSCs. Copyright © 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).**

**Hematopoiesis, hematopoietic stem cells, and aging of hematopoietic stem cells**

The mammalian blood system consists of many distinct types of differentiated cells with specialized functions like erythrocytes, platelets, T and B lymphocytes, myeloid cells, mast cells, natural killer cells, and dendritic cells. Many of these mature blood cells are short-lived and, thus, need to be replaced at a rate of more than one million cells per second in the adult human [1]. This continuous replenishment depends on the activity of hematopoietic progenitor cells (HPCs) and, ultimately, hematopoietic stem cells (HSCs). HSCs are defined functionally by their ability to self-renew, as well as to differentiate into more mature progenitor cells and, therefore, to provide long-term reconstitution potential of the blood in lethally irradiated recipients over serial transplantation experiments. HSCs were first described in the 1960s by Becker [2], Sim-

inovitch [3], Till and McCulloch [4], and Wu [5] as a population of bone marrow (BM) cells capable of forming myelo-erythroid colonies in the spleens of irradiated recipient mice. Within these colonies a very small subset of cells displayed the ability to self-renew and to differentiate into all types of blood cells. HSCs reside predominantly in the BM at a frequency of 2 to 5 cells in  $10^5$  total BM cells. Phenotypically, HSCs can be purified to near homogeneity using combinations of cell surface marker staining or dye efflux properties with fluorescence-activated cell sorting. Common marker combinations for long-term (LT)-HSCs are  $\text{Lin}^-$  (lineage-negative),  $\text{Sca-1}^+$ ,  $\text{c-Kit}^+$ ,  $\text{CD34}^-$ ,  $\text{Flk2}^-$  or side population (high Hoechst efflux),  $\text{Lin}^-$ ,  $\text{Sca-1}^+$ , and  $\text{c-Kit}^+$ . SLAM family markers ( $\text{CD150}^+$ ,  $\text{CD48}^-$ ,  $\text{CD41}^-$ ) can be used to further distinguish myeloid biased LT-HSCs [6–8].

The number and potential of HSCs are controlled via complex regulatory mechanisms involving tight molecular and cellular control of quiescence (G0 state of the cell cycle), self-renewal (maintenance and expansion), differentiation (production of mature blood cells), apoptosis

Offprint requests to: Hartmut Geiger, Institute for Molecular Medicine, University of Ulm, James Franck-Ring 11c, 89081 Ulm, Germany; E-mail: [hartmut.geiger@uni-ulm.de](mailto:hartmut.geiger@uni-ulm.de); [hartmut.geiger@cchmc.org](mailto:hartmut.geiger@cchmc.org)

(clearance of damaged cells), and localization, as well as cell architecture. Under steady-state conditions, HSCs are a largely quiescent, slowly cycling cell population, where only 8% of cells enter the cell cycle per day [9]. However, in response to stress, HSCs exit quiescence, expand, and differentiate. The mostly quiescent status of HSCs is thought to be a protective mechanism against endogenous stress caused by reactive oxygen species and DNA replication [10]. Quiescence is different from terminal differentiation, senescence, and apoptosis because it is reversible and functionally unlike cell cycle arrest. When quiescence is disrupted, HSCs might display premature exhaustion, impaired self-renewal, and loss of repopulating capacity [11,12]. The balance between quiescence and proliferation is usually strictly controlled (positively as well as negatively) by the intrinsic and extrinsic (niche) mechanisms of HSCs.

Contrary to a common assumption that cell loss is tightly associated with aging, the number of phenotypic HSCs actually increases in both mice and humans [13,14]. There are two- to tenfold more HSCs present in the aged BM than in young marrow [13,15,16]. Under stress, as in serial transplantation assays, for example, aged HSCs exhibit a diminished regenerative potential as consequence of a lower long-term self-renewal capacity [17–19]. Aged HSCs also present with heightened replicative stress on cycling and decreased ribosomal biogenesis [20]. Additionally, their ability to home to the BM is reduced by a factor of 2 [21]. Furthermore, young and aged HSCs occupy distinct niches within the BM as seen in their localization relative to the endosteum [22]. Aged HSCs exhibit impaired adhesive properties to stroma cells and, in turn, can be better mobilized into the blood compared with young HSCs [22]. Genomewide expression studies comparing young and aged HSCs have identified a general downregulation of genes involved in lymphopoiesis and an upregulation of myeloid genes in aged HSCs, which is consistent with their myeloid bias [23]. Clinically, aging of the hematopoietic system is correlated to anemia, decreased competence of the adaptive immune system, and increased incidence of myeloid diseases (reviewed by Geiger et al. [24]). These aging-associated changes can be attributed at least in part to aging of HSCs. Aged HSCs are deficient in their ability to support erythropoiesis and exhibit a markedly decreased output of cells from the lymphoid lineage, whereas the myeloid lineage output is maintained or even increased compared with young HSCs. Recent exciting developments in the field, driven primarily by large-scale high-throughput sequencing approaches to human blood cells, suggest a highly polyclonal hematopoiesis in young individuals that is transformed into clonal hematopoiesis on aging, starting at the age of 70. This shift, from around 1,000 active HSCs to a few active clones, might also be an additional driver for the development of hematologic diseases [25], as mutations in genes associated with aging-associated leukemia, such as DNMT3A, TET2, JAK2, ASXL1, SF3B1, and SRSF2, have been found to be associated with clonality [26–28].

Finally, aged HSCs present with increased activity of the cell division control protein 42 (CDC42), a small Rho GTPase. The increased activity of CDC42 leads to loss of cell polarity in aged HSCs involving tubulin, CDC42, and the random nuclear distribution of acetylated H4K16 [29]. Activated levels of Cdc42 activity are causative for aging of murine HSCs [29]. In addition, epigenetic programs that maintain HSC function in young decline with age, demonstrated by changes in DNA methylation patterns on HSC aging, for example [23,30].

### DNA damage in aging of HSCs

A controversially discussed cell-intrinsic factor driving HSC aging is DNA damage. HSCs are responsible for maintaining tissue homeostasis throughout a lifetime. It is therefore critical for HSCs to maintain their genomic integrity to reduce the risk of either BM failure or transformation. The paradigm of the DNA damage theory of stem cell aging states that aging-associated changes in the DNA repair system in HSCs, together with changes in cell cycle regulation caused by increased DNA damage with age [31,32], are thought to result in elevated DNA mutations, which then causally contribute to the decrease in HSCs function with age. The paradigm is in part based on the finding that mice lacking a distinct set of DNA damage repair proteins display reduced function of HSCs, including an impaired repopulating potential and an overall depletion of the HSC pool [32–41]. In contrast, in “naturally” aged mice, there is actually an expansion of the number of phenotypic stem cells as described above and not a depletion of the HSCs.

DNA damage constantly arises from DNA replication errors, spontaneous chemical reactions and assaults by external or metabolism-derived agents. It has been estimated that a single cell might undergo up to 100,000 DNA lesions per day. Endogenous sources for DNA damage include replication and recombination errors (error rate:  $10^{-10}$ /bp), spontaneous hydrolysis, and reactive metabolites created as a by-product of cellular metabolism like reactive oxygen species (ROS) [34]. These events and metabolites can cause abasic sites, base deamination, 8-oxoguanine lesions, base oxidations, and a variety of DNA strand breaks. DNA damage can also be induced by exogenous factors, such as mutagens present in the environment, ultraviolet light from the sun, chemicals, X-rays, and gamma irradiation as well as chemotherapeutic drugs causing base modifications, interstrand crosslinks, and single- and double-strand breaks. The most severe forms of DNA damage are DNA double-strand breaks (DSBs), which arise at an estimated frequency of 10 DSBs/cell/day. These breaks can be intentional in the case of V(D)J recombination and class switch in B lymphocytes or accidental and unintentional. DSBs arise from ROS, gamma irradiation, mechanical stress, defective telomere processing, chemotherapeutic drugs, and replication fork collapse.

DNA damage, regardless of which type, leads to a cascade of cellular events known as the DNA damage response (DDR). The single components of these cascades can be classified into four functional groups: damage sensors, signal transducers, repair effectors, and arrest or death effectors. The outcome of DNA damage for the cell is variable and depends on potency of the damage, cell type, speed of DNA repair, p53 activation, and cell cycle stage of the cell [42,43]. The first step after a DNA DSB occurs involves proteins sensing the damage and activating the DDR. After the recognition of a DNA DSB, transducer proteins become activated, and signaling cascades are set in motion. ATM (ataxia telangiectasia mutated) and ATR (ATM and Rad3-related) are the main transducer proteins and, once activated, promote the DDR through phosphorylation-dependent recruitment of additional factors to sites of DNA DSBs. A very important modification at DSBs is the phosphorylation of histone H2AX, referred to as  $\gamma$ H2AX. The DNA around the phosphorylated form of the histone becomes less condensed, and a cascade of effector protein assembly is initiated. Activation of downstream targets of ATM (including Chk2 and subsequently p53), as well as ATR signaling (leading to Chk1 and CDC25A phosphorylation), can result in various different cellular outcomes like transient cell cycle arrest, apoptosis, senescence, or differentiation.

During transient cell cycle arrest, repair processes are initiated [44–46]. In case of DNA DSBs, two distinct repair pathways are usually activated, homologous recombination (HR) and non-homologous end joining (NHEJ). Because of the end-processing of DNA strands and a subsequent direct ligation of the break, NHEJ generally leads to small deletions and is thus thought to be error-prone and to result in DNA mutations [47]. In contrast, HR, which is based on a homologous DNA template (sister chromatid or homologous chromosome), is seen as an error-free process with respect to DNA mutations. HSCs mostly residing in G0 phase of the cell cycle are thought to be susceptible to undergo the error-prone NHEJ pathway to repair DNA DSBs arising from low-dose irradiation, thus making the cells vulnerable to acquiring mutations via faulty NHEJ [48]. In contrast to this observation, Insinga et al. showed an up-regulation of p21 in HSCs after irradiation followed by cell cycle entry that could enable the cells to use the error-free HR pathway to repair DNA DSBs [49]. More committed progenitor cells, however, underwent p53-dependent apoptosis because of irradiation, illustrating the difference in DNA damage response between stem cells and their progeny. Additionally, Beerman et al. [50] found that quiescent HSCs acquire DNA damage on aging, but when these cells start to cycle, the damage becomes repaired.

Alternatively, if repair is impossible, cells undergo apoptosis, senescence, or in case of stem cells, also differentiation. Published data indicate that DNA DSBs are very potent inducers of cellular senescence, implying that persistent DDR signaling confers senescent growth arrest [51,52].

In addition, differentiation in response to DNA damage occurs in various tissues including HSCs, melanocytic stem cells, and embryonic stem cells [45,46,53]. In HSCs, DNA damage induced by telomere attrition or DNA DSBs leads to an upregulation of the transcription factor Batf, resulting in induction of lymphoid differentiation of HSCs [46]. DNA damage induces apoptosis by both p53-dependent and p53-independent pathways. In lymphocytes and germ cells, apoptosis even represents the primary response to DNA damage [54]. In the context of HSCs, premature differentiation, senescence, and apoptosis as possible consequences of DNA damage are double-edged swords. They can be beneficial by removing damaged cells, but might at the same time lead to depletion and exhaustion of the stem cell pool.

What kind of phenotype in the hematopoietic system is present in animals with genetic deletions in genes linked to DNA damage repair and the DDR? For example, mice deleted for the ATM gene exhibit increased IR sensitivity and decreased T-cell numbers. HSCs from these mice have increased ROS levels and present with a decrease in number and function on aging, leading to progressive BM failure [34,55,56]. Knockout of any component of the MRN complex, as well as deletion of BRCA2, results in embryonic lethality. A hypomorphic Rad50<sup>k22m</sup> mutation in mice leads to early death accompanied by B-cell lymphoma and BM failure. This is due mostly to p53-dependent apoptosis and loss of HSC function [57]. Inactivation of genes involved in NHEJ illustrated their essential function in lymphocyte development, as components of NHEJ are critical for V(D)J recombination. Mice with a LigIV<sup>y288c</sup> hypomorphic mutation are immunodeficient and display severe HSC defects, such as impaired repopulating potential and decreased self-renewal [36]. Mice devoid of Ku70 or Ku80 end-binding proteins exhibit self-renewal defects, impaired differentiation and proliferation potential, as well as increased apoptosis within the HSC compartment [32,58]. In a mouse model in which phosphorylation sites of DNA-PKcs were mutated (3A mutation, 3-alanine substitution of Thr2605, 2634 + 2643) called DNA-PKcs<sup>3A/3A</sup>, BM failure and loss of HSCs in fetal liver could be observed. This impairment of HSC proliferation is caused by p53-dependent apoptosis resulting from severe DNA damage. Because p53 is also involved in the DDR, it is interesting to note that mice with varying p53 activities display distinct hematopoietic problems. Reduced p53 activity in heterozygous p53<sup>+/-</sup> mice is accompanied by an increase in HSC proliferation. A p53 hypomorphic mutation (p53<sup>+m</sup>) displaying higher p53 activity than in wild-type mice presented with decreased HSC frequency, repopulating capacity, and proliferation [59]. In summary though, mutations in most of the genes linked to DNA damage response so far did not result in the “aging-characteristic” initial expansion of the number of phenotypic HSCs, rendering a central role for these genes and the

pathways they represent with respect to physiologic aging of the hematopoietic system not likely.

Analyses of young and aged HSCs with respect to changes in the frequency of DNA damage and the frequency of DNA mutations (comet assay,  $\gamma$ H2AX foci, DNA mutation frequency, loss of heterozygosity assays) revealed a minor increase in these parameters on aging in steady-state hematopoiesis [32,50,60,61]. Elevated levels of  $\gamma$ H2AX foci in aged HSCs are also associated with replication stress, as well as ribosomal biogenesis stress, and therefore might not be unequivocally associated with DNA damage (Table 1) [20].

In general, aged murine hematopoietic cells (either BM or peripheral blood, and independent of the type of mutation assay) exhibit a two- to threefold increase in mutation frequency in hematopoiesis compared with young cells [61–63], which is also in the range of changes in mutation frequency recently reported for human hematopoietic cells, determined via deep-sequencing approaches [26–28,64–67]. Interestingly, although the overall increase in mutation frequencies in blood cells was found to be again in the range of two- to threefold, a set of genes including DNMT3A, TET2, JAK2, ASXL1, SF3B1, or SRSF2 were frequently mutated, in both aging-associated leukemia and aging-associated changes in clonality. These genes function primarily in epigenetic regulation and splicing but are usually not associated with DNA repair or the DDR, implying that these pathways are not selected on aging of HSCs.

Although these data in aggregation confirm a mild two- to threefold aging-associated increase in the mutation frequency in hematopoiesis, the increase is linear and not exponential with respect to age, rendering a cause–consequence relationship to the exponential increase of leukemia on aging unlikely. Modeling of aging of HSCs populations based on evolutionary theories also indicates that accumulation of genetic changes within HSCs is not sufficient to alter selectivity and fitness of HSCs, and

identified non-cell autonomous mechanisms, also known as changes in the niche, as the major selective driving force for aging-associated leukemia [68]. Such conclusions are also supported by the observation that while a twenty-twofold increase in the mutational load [69] initiated cancer in the presence of a mutator gene type setting [70–72], a modest two- to threefold increase in mutational load in hematopoiesis in the context of the AML-ETO oncogene did not result in leukemia initiation [73] in mice *in vivo*. Finally, novel data from our laboratory indicated that the quality of the DDR in HSCs does not change on aging. HSCs, both young and old, enter the cell cycle *in vivo* upon DNA damage, without initiating a strong G1–S cell cycle arrest as reported for fibroblasts [61]. They also do not present with a marked difference in apoptosis *in vivo* on induction of DSBs. Second, in response to irradiation, both young and aged HSCs responded functionally identically, as revealed in competitive transplantation–irradiation–recovery experiments, in which young and aged HSCs directly competed in the same recipient animal *in vivo* in response to total-body irradiation [61]. Third, there was a significant decrease in the mutation frequency in both young and aged BM 4 months after total-body irradiation, and aged animals presented with a mutation frequency similar to that of young animals [61]. One explanation for such observations might be that deeply quiescent HSCs are the ones with few mutations because of their small number of cell divisions [74], whereas HSCs that already underwent a larger number of divisions, and thus most likely have a low level of mutations, instead apoptose or differentiate in response to irradiation. Therefore, it is possible that the deeply quiescent HSCs survive irradiation and support hematopoiesis after other HSCs have been eliminated by irradiation [10], further indicating the resilience of the hematopoietic system to acquire a large number of mutations in HSCs that might directly contribute to aging of HSCs and leukemia.

**Table 1.** DNA damage accumulation on aging in HSCs

Increased DNA damage and DNA mutations on aging in HSCs and the hematopoietic system contribute to aging of HSCs	
Yes	No
Accumulation of $\gamma$ H2AX foci, indicative of persistent DNA DSBs [14]	$\gamma$ H2AX foci can also indicate replication and ribosome biogenesis stress in aged HSCs [20]
Comet assay experiments in aged HSCs revealed a twofold increase in DNA damage level in steady state [50,61]	In aged hair follicle stem cells, $\gamma$ H2AX foci are associated with persistent chromatin alterations but not DNA DSBs [78]
Mutation frequency in human and murine BM is increased twofold upon aging [26,61,64,65]	DNA damage level decreased on cell cycle entry of aged HSCs [50]
Incidence of leukemia increases dramatically upon aging [77,79,80]	Mutation frequency in aged BM decreases upon DNA damage [61]
Mouse models with altered DNA damage response genes exhibited BM failure and depletion of the HSC pool [32,34,36,55–59,81]	In aging-associated leukemia, only very few driver mutations could be identified [27,28,66,67]
	In normal aging, there is an increase in the number of HSCs [13,14]

## Perspective

Because the accumulation of DNA mutations in HSCs on aging might not be linked directly to the functional decline of HSCs with age and an aging-associated exponential increase in the incidence of leukemia, what other mechanisms might contribute to these phenotypes? It could already be shown that aging of the HSC niche and environment plays an important role in selecting and expanding normal and preleukemic HSC and HPC clones on aging [75,76]. Thus, the concept of adaptive landscapes recently has been developed [77]. In this concept, the niche environment of HSCs changes on aging, influencing the functionality of HSCs. The mutations acquired over time might not influence the HSC per se. In addition to extrinsic factors, intrinsic alterations that are not mutations in DNA might ultimately contribute to HSC aging. We recently reported that HSCs change their polarity on aging, in both the cytoplasm and the nucleus. It thus might be possible that changes in the general architecture of the cell might also contribute to HSC aging. Changes in the three-dimensional arrangement of epigenetic marks and structural proteins might influence cell divisions in a way that reduces potential in daughter stem cells, for example, contributing to intrinsic HSC aging. In summary, multiple mechanisms might contribute to aging of HSCs and ultimately depend on the interplay between extrinsic and intrinsic cell factors.

## Acknowledgments

Work in the laboratory of H. Geiger was supported by National Institutes of Health Grants HL076604, DK077762, AG040118; the Deutsche Forschungsgemeinschaft (DFG: SFB 1074 and 1149, KFO142); the German Federal Ministry of Education and Research (BMBF: SyStaR, grant no. 0315894A); the Excellence program of the Baden-Württemberg Foundation; and funds from the German Scholar organization (GSO) and the European Commission (FP7 Marie Curie Initial Training Network MARRIAGE, grant no. 316964).

## References

- Ogawa M. Differentiation and proliferation of hematopoietic stem cells. *Blood*. 1993;81:2844–2853.
- Becker AJ, McCulloch EA, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. *Nature*. 1963;197:452–454.
- Siminovitch L, McCulloch EA, Till JE. The distribution of colony-forming cells among spleen colonies. *J Cell Physiol*. 1963;62:327–336.
- Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. *Radiat Res*. 1961;14:213–222.
- Wu AM, Till JE, Siminovitch L, McCulloch EA. Cytological evidence for a relationship between normal hematopoietic colony-forming cells and cells of the lymphoid system. *J Exp Med*. 1968;127:455–464.
- Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. *Cell*. 2005;121:1109–1121.
- Yang L, Bryder D, Adolfsson J, et al. Identification of Lin(–)Sca1(+) kit(+)CD34(+)Flt3– short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients. *Blood*. 2005;105:2717–2723.
- Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. *J Exp Med*. 1996;183:1797–1806.
- Cheshier SH, Morrison SJ, Liao X, Weissman IL. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. *Proc Natl Acad Sci U S A*. 1999;96:3120–3125.
- Walter D, Lier A, Geiselhart A, et al. Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells. *Nature*. 2015;520:549–552.
- Cheng T, Rodrigues N, Shen H, et al. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. *Science*. 2000;287:1804–1808.
- Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. *Nat Rev Immunol*. 2006;6:93–106.
- de Haan G, Nijhof W, Van Zant G. Mouse strain-dependent changes in frequency and proliferation of hematopoietic stem cells during aging: Correlation between lifespan and cycling activity. *Blood*. 1997;89:1543–1550.
- Rossi DJ, Bryder D, Zahn JM, et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. *Proc Natl Acad Sci U S A*. 2005;102:9194–9199.
- Chambers SM, Goodell MA. Hematopoietic stem cell aging: wrinkles in stem cell potential. *Stem Cell Rev*. 2007;3:201–211.
- Morrison SJ, Wandycz AM, Akashi K, Globerson A, Weissman IL. The aging of hematopoietic stem cells. *Nat Med*. 1996;2:1011–1016.
- Sudo K, Ema H, Morita Y, Nakauchi H. Age-associated characteristics of murine hematopoietic stem cells. *J Exp Med*. 2000;192:1273–1280.
- Kamminga LM, van Os R, Ausema A, et al. Impaired hematopoietic stem cell functioning after serial transplantation and during normal aging. *Stem Cells*. 2005;23:82–92.
- Janzen V, Forkert R, Fleming HE, et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. *Nature*. 2006;443:421–426.
- Flach J, Bakker ST, Mohrin M, et al. Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. *Nature*. 2014;512:198–202.
- Liang Y, Van Zant G, Szilvassy SJ. Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. *Blood*. 2005;106:1479–1487.
- Köhler A, Schmithorst V, Filippi MD, et al. Altered cellular dynamics and endosteal location of aged early hematopoietic progenitor cells revealed by time-lapse intravital imaging in long bones. *Blood*. 2009;114:290–298.
- Chambers SM, Shaw CA, Gatzka C, Fisk CJ, Donehower LA, Goodell MA. Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. *PLoS Biol*. 2007;5:e201.
- Geiger H, Denking M, Schirmbeck R. Hematopoietic stem cell aging. *Curr Opin Immunol*. 2014;29:86–92.
- McKerrell T, Vassiliou GS. Aging as a driver of leukemogenesis. *Sci Transl Med*. 2015;7:306fs38.
- Genovese G, Köhler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *N Engl J Med*. 2014;371:2477–2487.
- Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med*. 2014;371:2488–2498.
- McKerrell T, Park N, Moreno T, et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. *Cell Rep*. 2015;10:1239–1245.

29. Florian MC, Dörr K, Niebel A, et al. Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. *Cell Stem Cell*. 2012;10:520–530.
30. Beerman I, Bock C, Garrison BS, et al. Proliferation-dependent alterations of the DNA methylation landscape underlie hematopoietic stem cell aging. *Cell Stem Cell*. 2013;12:413–425.
31. Pietras EM, Warr MR, Passegué E. Cell cycle regulation in hematopoietic stem cells. *J Cell Biol*. 2011;195:709–720.
32. Rossi DJ, Bryder D, Seita J, Nussenzweig A, Hoeijmakers J, Weissman IL. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. *Nature*. 2007;447:725–729.
33. Geiger H, de Haan G, Florian MC. The ageing haematopoietic stem cell compartment. *Nat Rev Immunol*. 2013;13:376–389.
34. Ito K, Hirao A, Arai F, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. *Nature*. 2004;431:997–1002.
35. Navarro S, Meza NW, Quintana-Bustamante O, et al. Hematopoietic dysfunction in a mouse model for Fanconi anemia group D1. *Mol Ther*. 2006;14:525–535.
36. Nijnik A, Woodbine L, Marchetti C, et al. DNA repair is limiting for haematopoietic stem cells during ageing. *Nature*. 2007;447:686–690.
37. Parmar K, Kim J, Sykes SM, et al. Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. *Stem Cells*. 2010;28:1186–1195.
38. Prasher JM, Lalai AS, Heijmans-Antonissen C, et al. Reduced hematopoietic reserves in DNA interstrand crosslink repair-deficient *Ercc-/-* mice. *EMBO J*. 2005;24:861–871.
39. Reese JS, Liu L, Gerson SL. Repopulating defect of mismatch repair-deficient hematopoietic stem cells. *Blood*. 2003;102:1626–1633.
40. Ruzankina Y, Pinzon-Guzman C, Asare A, et al. Deletion of the developmentally essential gene *ATR* in adult mice leads to age-related phenotypes and stem cell loss. *Cell Stem Cell*. 2007;1:113–126.
41. Zhang QS, Marquez-Loza L, Eaton L, et al. *Fancd2-/-* mice have hematopoietic defects that can be partially corrected by resveratrol. *Blood*. 2010;116:5140–5148.
42. d'Adda di Fagagna F. Living on a break: Cellular senescence as a DNA-damage response. *Nat Rev Cancer*. 2008;8:512–522.
43. Blanpain C, Mohrin M, Sotiropoulou PA, Passegué E. DNA-damage response in tissue-specific and cancer stem cells. *Cell Stem Cell*. 2011;8:16–29.
44. Bartek J, Lukas J. DNA Damage checkpoints: from initiation to recovery or adaptation. *Curr Opin Cell Biol*. 2007;19:238–245.
45. Inomata K, Aoto T, Binh NT, et al. Genotoxic stress abrogates renewal of melanocyte stem cells by triggering their differentiation. *Cell*. 2009;137:1088–1099.
46. Wang J, Sun Q, Morita Y, et al. A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. *Cell*. 2012;148:1001–1014.
47. Khanna KK, Jackson SP. DNA double-strand breaks: Signaling, repair and the cancer connection. *Nat Genet*. 2001;27:247–254.
48. Mohrin M, Bourke E, Alexander D, et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. *Cell Stem Cell*. 2010;7:174–185.
49. Insinga A, Cicalese A, Faretta M, et al. DNA Damage in Stem Cells Activates p21, Inhibits p53, and Induces Symmetric Self-Renewing Divisions. *Proc Natl Acad Sci U S A*. 2013;110:3931–3936.
50. Beerman I, Seita J, Inlay MA, Weissman IL, Rossi DJ. Quiescent hematopoietic stem cells accumulate DNA damage during aging that is repaired upon entry into cell cycle. *Cell Stem Cell*. 2014;15:37–50.
51. Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. *Genes Dev*. 1994;8:2540–2551.
52. Nakamura AJ, Chiang YJ, Hathcock KS, et al. Both telomeric and non-telomeric DNA damage are determinants of mammalian cellular senescence. *Epigenetics Chromatin*. 2008;1:6.
53. Li M, He Y, Dubois W, Wu X, Shi J, Huang J. Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells. *Mol Cell*. 2012;46:30–42.
54. Lee HW, Blasco MA, Gottlieb GJ, Horner JW II, Greider CW, DePinho RA. Essential role of mouse telomerase in highly proliferative organs. *Nature*. 1998;392:569–574.
55. Barlow C, Hirotsune S, Paylor R, et al. *Atm*-deficient mice: A paradigm of ataxia telangiectasia. *Cell*. 1996;86:159–171.
56. Ito K, Hirao A, Fumio Arai F, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. *Nat Med*. 2006;12:446–451.
57. Bender CF, Sikes ML, Sullivan R, et al. Cancer predisposition and hematopoietic failure in *Rad50S/S* Mice. *Genes Dev*. 2002;16:2237–2251.
58. Kenyon J, Gerson SL. The role of DNA damage repair in aging of adult stem cells. *Nucleic Acids Res*. 2007;35:7557–7565.
59. Dumble M, Moore L, Chambers SM, et al. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. *Blood*. 2007;109:1736–1742.
60. Rube CE, Fricke A, Widmann TA, et al. Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging. *PLoS One*. 2011;6:e17487.
61. Moehrle BM, Nattamai K, Brown A, et al. Stem cell-specific mechanisms ensure genomic fidelity within HSCs and upon aging of HSCs. *Cell Rep*. 2015;13:2412–2424.
62. Dempsey JL, Pfeiffer M, Morley AA. Effect of dietary restriction on in vivo somatic mutation in mice. *Mutat Res*. 1993;291:141–145.
63. Vijg J, Busuttill RA, Bahar R, Dollé ME. Aging and genome maintenance. *Ann N Y Acad Sci*. 2005;1055:35–47.
64. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med*. 2013;368:2059–2074.
65. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. *Cell*. 2012;150:264–278.
66. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. *Nat Med*. 2014;20:1472–1478.
67. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. *Blood*. 2013;122:3616–3627; quiz 3699.
68. Rozhok AI, Salstrom JL, DeGregori J. Stochastic modeling reveals an evolutionary mechanism underlying elevated rates of childhood leukemia. *Proc Natl Acad Sci*. 2016;113:1050–1055.
69. Geiger H, Schleimer D, Nattamai KJ, Dannenmann SR, Davies SM, Weiss BD. Mutagenic potential of temozolomide in bone marrow cells in vivo. *Blood*. 2006;107:3010–3011.
70. Kushner BH, Laquaglia MP, Kim Kramer K, Modak S, Cheung NK. Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: Possible leukemogenic role of temozolomide. *Pediatr Blood Cancer*. 2008;51:552–554.
71. Noronha V, Berliner N, Ballen KK, et al. Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature. *Neuro Oncol*. 2006;8:280–283.
72. Su YW, Chang MC, Chiang MF, Hsieh RK. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. *J Neurooncol*. 2005;71:315–318.
73. Krejci O, Wunderlich M, Geiger H, et al. p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. *Blood*. 2008;111:2190–2199.
74. Tomasetti C, Vogelstein B. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. *Science*. 2015;347:78–81.

75. Vas V, Senger K, Dörr K, Niebel A, Geiger H. Aging of the micro-environment influences clonality in hematopoiesis. *PLoS One*. 2012;7:e42080.
76. Vas V, Wandhoff C, Dörr K, Niebel A, Geiger H. Contribution of an aged microenvironment to aging-associated myeloproliferative disease. *PLoS One*. 2012;7:e31523.
77. Rozhok AI, Salstrom JL, DeGregori J. Stochastic modeling reveals an evolutionary mechanism underlying elevated rates of childhood leukemia. *Proc Natl Acad Sci U S A*. 2016;113: 1050–1055.
78. Schuler N, Rube CE. Accumulation of DNA damage-induced chromatin alterations in tissue-specific stem cells: The driving force of aging? *PLoS One*. 2013;8:e63932.
79. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. *Br J Cancer*. 1954;8:1–12.
80. Nordling CO. A new theory on cancer-inducing mechanism. *Br J Cancer*. 1953;7:68–72.
81. Tothova Z, Kollipara R, Huntly BJ, et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. *Cell*. 2007;128:325–339.